Information Provided By: 
Fly News Breaks for December 2, 2016
BLUE
Dec 2, 2016 | 07:57 EDT
Maxim analyst Jason McCarthy said the early data on bluebird bio's bb2121 show it is inducing clinical responses, including complete responses, "essentially in the absence of" CRS and neuro-toxicity. While waiting to see if this trend continues, given the positive bb2121 data so far in multiple myeloma, McCarthy raised his price target on bluebird shares to $87 from $57. He keeps a Buy rating on the stock, noting that he is now factoring in a bb2121 launch in 2021.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
